Eris Lifesciences Limited, one of India’s leading branded formulations manufacturers, has announced that a manufacturing unit at its Ahmedabad campus has received approval from ANVISA, Brazil’s national health regulatory authority.

The approval follows a successful inspection conducted in May 2025 and paves the way for Eris to enter Brazil, the largest pharmaceutical market in South America. Company officials noted that the clearance by a stringent regulator such as ANVISA stands as a strong endorsement of the company’s adherence to Good Manufacturing Practices (GMP) and robust quality systems.

The Ahmedabad facility has also been successfully inspected by several other international regulatory agencies earlier this year, further reinforcing its compliance with global quality standards.

With this milestone, Eris Lifesciences is now positioned to expand its international presence and tap into one of the most dynamic and high-potential pharmaceutical markets in the region.